雷珠单抗治疗DME与RVO-ME患者的临床效果  

The clinical effect of ranibizumab drugs for the treatment of DME and RVO-ME patients

作　　者：李俊莲[1] 王岩[1] 

机构地区：[1]内蒙古医科大学附属医院眼科,内蒙古呼和浩特市010050

出　　处：《热带医学杂志》2016年第12期1552-1553,1577,共3页Journal of Tropical Medicine

摘　　要：目的分析雷珠单抗在治疗糖尿病黄斑水肿(DME)与视网膜静脉阻塞性黄斑水肿(RVO-ME)的效果。方法随机选取2014年2月至2015年10月于内蒙古医科大学附属医院治疗的DME和RVO-ME患者共200例,共330只患眼。其中DME组有170只患眼,ROV-ME组有160只患眼。患者注射雷珠单抗,用量为0.5 mg/0.5 ml,注射前1 d,后1 d、2周、4周分别进行回访,观察患者最佳矫正视力(BCVA)和中央黄斑厚度(CST)。结果注射雷珠抗体1 d、2周、4周后,两组患者的BCVA逐渐改善,差异有统计学意义(P<0.05);注射4周后,两组患者的CST明显降低,差异有统计学意义(P<0.05);两组在治疗效果方面差异无统计学意义。两组患者在注射雷珠单抗后及后期回访中均未出现与雷珠单抗和玻璃体腔注射有关的并发症。结论雷珠单抗治疗DME与RVO-ME患者可以有效消除水肿,提升视力,安全性好。Objective To analyze the effect of ranibizumab on the treatment of diabetic macular edema （DME） and retinal vein occlusion macular edema （RVO-ME）. Methods 200 DME and RVO-ME patients were randomly selected in February 2014- October 2015 in our hospital; they suffered from a total of 330 eyes. Patients were divided into two groups： DME170 affected eyes, ROV-ME160 affected eyes. Patients were injection with Ranibizumab, 0.5 mg/0.5 ml. Best corrected visual acuity （BCVA） and central macular thickness （CST） of the patient was measured before, 1 day, two weeks and four weeks after injection. Results The BCVA of the patients at 1 day, two weeks and four weeks after injection were significantly higher those of before injection （P〈0.05）. 4 weeks after injection, CST of patients were significantly increased （P〈0.05）; there is not much difference in outcome between the DME170 affected eyes, ROV-ME160 affected eyes groups （P〉0.05）. Conclusion Ranibizumab showed a significant effect on the treatment of DME and RVO-ME, and could effectively eliminate edema and improve vision.

关 键 词：雷珠单抗 糖尿病黄斑水肿 视网膜静脉阻塞性黄斑水肿 

分 类 号：R774[医药卫生—眼科]